Seres Therapeutics (MCRB) stock price, revenue, and financials

Seres Therapeutics market cap is $2.4 b, and annual revenue was $34.51 m in FY 2019

$2.4 B

MCRB Mkt cap, 22-Sept-2020

$6 M

Seres Therapeutics Revenue Q2, 2020
Seres Therapeutics Net income (Q2, 2020)-20.7 M
Seres Therapeutics EBIT (Q2, 2020)-20.5 M
Seres Therapeutics Cash, 30-Jun-202061.5 M
Seres Therapeutics EV2.3 B

Seres Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

73.9m54.5m36.1m85.8m65.1m

Accounts Receivable

1.8m

Prepaid Expenses

5.1m6.8m3.6m

Inventories

2.5m5.1m

Current Assets

207.6m198.4m155.1m92.7m100.2m

PP&E

7.8m36.1m32.9m26.3m19.5m

Total Assets

216.9m272.6m189.5m120.5m132.4m

Accounts Payable

5.4m7.6m7.0m6.4m4.9m

Current Liabilities

10.9m30.5m31.6m42.0m46.0m

Long-term debt

1.3m40.3m

Total Debt

40.3m

Total Liabilities

140.0m128.8m168.5m180.8m

Common Stock

40.0k41.0k70.0k

Additional Paid-in Capital

287.9m306.9m324.4m341.3m411.3m

Retained Earnings

(82.6m)(174.2m)(263.6m)(389.4m)(459.6m)

Total Equity

205.4m132.6m60.7m(48.0m)(48.3m)

Financial Leverage

1.1 x2.1 x3.1 x-2.5 x-2.7 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

36.3m69.7m193.2m59.8m55.6m41.9m33.6m46.0m47.2m58.0m55.7m53.6m102.2m49.3m54.9m61.5m

Accounts Receivable

6.7m1.6m1.7m2.1m2.9m

Prepaid Expenses

2.3m3.0m3.6m5.2m5.1m5.2m4.8m5.3m4.3m5.5m6.6m7.5m5.2m4.1m3.4m5.8m

Current Assets

94.1m222.4m306.8m217.1m208.4m192.3m176.1m176.6m126.5m101.5m79.4m67.8m109.0m89.6m80.6m72.7m

PP&E

3.3m4.5m16.1m27.0m34.6m36.1m34.8m33.7m31.5m29.9m28.1m24.6m22.9m21.2m17.8m16.3m

Total Assets

101.3m227.0m324.5m306.2m297.5m244.9m216.3m211.9m159.4m133.0m109.0m107.0m146.1m124.2m110.6m100.7m

Accounts Payable

1.7m2.1m5.8m4.5m4.2m5.6m3.9m5.4m5.4m5.2m6.5m3.9m4.8m4.5m5.5m4.2m

Short-term debt

1.2m4.6m4.8m

Current Liabilities

5.6m4.8m24.8m27.3m31.9m27.2m25.7m27.0m35.2m36.8m39.0m41.6m43.1m42.2m44.1m44.2m

Long-term debt

727.0k19.1m18.0m16.8m39.2m38.0m

Total Debt

727.0k1.3m19.1m18.0m16.8m43.8m42.8m

Total Liabilities

6.4m4.8m134.6m138.8m143.5m133.4m128.4m126.4m149.4m146.2m139.6m176.9m164.1m156.4m172.3m166.3m

Common Stock

31.0k39.0k39.0k40.0k40.0k40.0k40.0k40.0k40.0k40.0k41.0k41.0k70.0k70.0k72.0k75.0k

Additional Paid-in Capital

143.2m285.1m292.0m297.5m302.9m311.2m315.7m320.2m328.4m332.9m337.5m343.8m406.4m408.6m417.8m434.6m

Retained Earnings

(48.4m)(63.0m)(102.3m)(130.2m)(148.9m)(199.7m)(227.7m)(234.6m)(318.3m)(346.1m)(368.1m)(413.7m)(424.5m)(440.9m)(479.5m)(500.2m)

Total Equity

94.9m222.2m189.8m167.4m154.0m111.5m87.9m85.5m10.0m(13.3m)(30.6m)(69.8m)(18.0m)(32.2m)(61.6m)(65.6m)

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.1 x1 x1.7 x1.8 x1.9 x2.2 x2.5 x2.5 x15.9 x-10 x-3.6 x-1.5 x-8.1 x-3.9 x-1.8 x-1.5 x

Seres Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(54.8m)(91.6m)(89.4m)(98.9m)(70.3m)

Depreciation and Amortization

728.0k4.2m7.3m7.9m7.6m

Accounts Receivable

(1.8m)

Inventories

(2.5m)(2.6m)

Accounts Payable

2.7m3.6m(856.0k)(353.0k)(1.5m)

Cash From Operating Activities

(40.8m)43.9m(75.5m)(62.9m)(76.5m)

Purchases of PP&E

(4.4m)(21.5m)(4.7m)(1.9m)(1.0m)

Cash From Investing Activities

(137.1m)(65.5m)57.0m112.3m(30.5m)

Cash From Financing Activities

137.7m2.1m83.0k268.0k86.2m

Net Change in Cash

(18.5m)49.7m(20.8m)

Interest Paid

163.0k109.0k1.0k221.0k

Seres Therapeutics Ratios

USDQ2, 2015

Financial Leverage

1.1 x

Seres Therapeutics Employee Rating

3.617 votes
Culture & Values
3.4
Work/Life Balance
3.6
Senior Management
2.9
Salary & Benefits
3.4
Career Opportunities
3.3
Source